Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Strategic Planning Group LLC

Strategic Planning Group LLC decreased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,309 shares of the medical equipment provider's stock after selling 890 shares during the period. Intuitive Surgical accounts for approximately 1.2% of Strategic Planning Group LLC's holdings, making the stock its 26th biggest holding. Strategic Planning Group LLC's holdings in Intuitive Surgical were worth $6,096,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Onefund LLC boosted its stake in shares of Intuitive Surgical by 1.9% during the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 18 shares during the period. AlphaCore Capital LLC raised its holdings in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after buying an additional 18 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Intuitive Surgical by 2.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock worth $390,000 after acquiring an additional 19 shares during the last quarter. Accredited Investors Inc. boosted its holdings in Intuitive Surgical by 1.9% during the 4th quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after acquiring an additional 19 shares during the period. Finally, Second Line Capital LLC grew its position in Intuitive Surgical by 3.4% in the 4th quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after acquiring an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ISRG. Barclays dropped their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. BTIG Research set a $560.00 price target on Intuitive Surgical and gave the company a "buy" rating in a research note on Monday, April 14th. Truist Financial dropped their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Piper Sandler reduced their price target on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Finally, Robert W. Baird lowered their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $596.05.

Insider Activity

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the sale, the executive vice president now owns 5,224 shares in the company, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian Edward Miller sold 8,900 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the sale, the executive vice president now directly owns 5,758 shares of the company's stock, valued at $2,793,033.06. This trade represents a 60.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 25,716 shares of company stock valued at $12,831,288 over the last ninety days. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $0.11 during trading on Thursday, hitting $558.06. The company's stock had a trading volume of 1,241,906 shares, compared to its average volume of 1,646,647. Intuitive Surgical, Inc. has a fifty-two week low of $405.08 and a fifty-two week high of $616.00. The company has a market cap of $200.02 billion, a PE ratio of 87.06, a P/E/G ratio of 5.85 and a beta of 1.67. The business's 50 day simple moving average is $519.52 and its 200-day simple moving average is $538.95.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same period last year, the business earned $1.50 EPS. Analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.